GlobeNewswire
-
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency
28/09/2026 -
Olivaro Drops Publishes 2026 Supplement Facts and Serving Information for Its Liquid Dietary Supplement
28/09/2026 -
Rancho Bernardo Dentistry Releases Patient Guide Comparing Professional Teeth Whitening and At-Home Kits
28/09/2026 -
Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results
28/09/2026 -
Natural Alternatives International, Inc. Announces Fiscal 2026 Q4 and YTD Results
28/09/2026 -
Nyxoah Appoints Liam Kelly as Chief Executive Officer
28/09/2026 -
Nyxoah Nomme Liam Kelly au Poste de Chief Executive Officer
28/09/2026 -
MedLegalPsych Launches Independent Psychiatric Assessment and IME Services in Winnipeg for Insurers, Employers, and Disability Case Managers
28/09/2026 -
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
28/09/2026 -
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
28/09/2026 -
Interra Health Named Quarterfinalist in the 2026 Digital Health & AI Awards
28/09/2026 -
ProText Mobility Issues Significant Inter-Quarter Shareholder Update: ABSA Confirms Inaugural Digital-Asset Custody Pilot as TXTM Advances Global RWA and Uplist Strategy
28/09/2026 -
Fetal surgeon Payam Saadai, MD, to join Rady Children’s Health Orange County
28/09/2026 -
EvergreenHealth receives transformative $100M gift from Dean Weidner
28/09/2026 -
Children’s National receives $4 million gift for healing arts, nature and play
28/09/2026 -
EssilorLuxottica: Disclosure of transactions in own shares
28/09/2026 -
EssilorLuxottica: Déclaration de transactions sur actions propres
28/09/2026 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026
28/09/2026 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 39 - 2026
28/09/2026
Pages